Abivax S.A. (ABVX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Paris, France. Le PDG actuel est Didier Blondel.
ABVX a date d'introduction en bourse 2023-10-20, 69 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $8.25B.
Abivax S.A. is a French biopharmaceutical company focused on discovering and developing drugs for inflammatory diseases, infectious diseases, and cancer. The company's lead candidate, ABX464, is in Phase IIb clinical trials for ulcerative colitis and Crohn's disease, with additional Phase IIa development for rheumatoid arthritis and completed Phase IIa trials for HIV viral remission. Abivax also develops ABX196, an immune-enhancing therapeutic in Phase 1/2 trials for hepatocellular carcinoma, alongside ongoing research programs targeting dengue fever, influenza, and respiratory syncytial virus. The company operates through partnerships with leading French research institutions including the French National Centre for Scientific Research, University of Montpellier, and Institut Curie. Founded in 2013 and headquartered in Paris, Abivax is advancing a diversified pipeline of novel immunotherapeutic candidates.
